Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease - Archive ouverte HAL Access content directly
Journal Articles Annals of the Rheumatic Diseases Year : 2018

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease

(1, 2) , (3, 4) , , (5) , , (6) , (7) , (8) , (9) , (10, 11, 12) , (13) , , , , , ,
1
2
3
4
5
6
7
8
9
10
11
12
13

Keywords

Dates and versions

hal-01881123 , version 1 (25-09-2018)

Identifiers

Cite

Cem Gabay, Bruno Fautrel, Jürgen Rech, François Spertini, Eugen Feist, et al.. Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\textquoterights disease. Annals of the Rheumatic Diseases, 2018, 13, pp.annrheumdis--2017--212608. ⟨10.1136/annrheumdis-2017-212608⟩. ⟨hal-01881123⟩
60 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More